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Background: Prostate cancer (PCa) is the most commonly diagnosed cancer and kills about 28,000 American men
annually. Although progress has been made in understanding the molecular features of different forms of the
disease, PCa is considered incurable when it becomes resistant to standard therapies. Prostate specific antigen (PSA)
test has been a gold standard of diagnosis for PCa, however, it can result in lead to the unnecessary biopsies and
treatment of indolent cancers due to the low specificity. Thus, the limitations of PSA screening for PCa have
prompted much focus on strategies how to enhance the accuracy of PSA for distinction between aggressive
and indolent cancers.
Discussion: Studies of miRNAs in PCa patients have suggested differentially expressed miRNAs between
healthy controls and those with PCa, providing potential biomarker candidates using body fluids including
urine and blood. Virus infection has been considered to associate with PCa incidence. Virus infected PCa cells may shed
extracellular vesicles and communicate with neighboring cells, which were not infected yet, however, no mechanistic
approaches were performed to understand the biology. The miRNAs composition in the shedding extracellular vesicles,
and its role in PCa are completely undefined. In the near future, new insights to connect between the viral derived
miRNAs and PCa progression might provide an opportunity to diagnose, risk prediction and therapeutic strategies.
Summary: The goal of this debate article is to provide a short review on miRNAs, virus infection and viral encoded
miRNAs in PCa, with a primary focus on circulating miRNAs as potential non-invasive biomarkers for PCa patients.
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Prostate cancer (PCa) remains one of the most commonly
diagnosed malignant tumor in men and the second leading
cause of death from cancer [1–3]. Several new drugs in-
cluding Radium-223, Cabazitaxel, Sipuleucel-T, Abirater-
one, and Enzalutamide have shown significantly improved
survival in castration-resistant metastatic disease (CRPC)
patients in Phase 3 trials [4–8]. For early detection of PCa,
urologists rely on serum prostate-specific antigen (PSA)
testing or digital rectal examination (DRE) [9]. Serum PSA
testing has successfully achieved a dramatic increase of PCa
detection, however, PSA testing has a low specificity be-
cause an increase of PSA level is not a PCa-specific event.* Correspondence: Jayoung.Kim@cshs.org; wjkim@chungbuk.ac.kr
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(http://creativecommons.org/publicdomain/zeSerum PSA levels are also elevated in men with benign
prostatic hyperplasia and prostatitis. Limitations of DRE for
the early detection derived from its low accuracy and the
dependence on highly trained clinicians. Such a lack of
PCa-specific early detection tool leads to create unneces-
sary biopsies or severe treatments for indolent PCa [2]. De-
velopment of methods of prebiopsy risk stratification and
more simple, noninvasive, sufficiently sensitive and specific
tests for PCa diagnosis would allow the stratification of PCa
patients who are at the very early stage of disease [1, 10].
Current efforts to improve the accuracy of PSA and de-
velop new biomarkers for PCa may hold the promise of im-
proving the screening, diagnosis, and monitoring of
prostate cancer. PCA3, a non-coding and large chain RNA
that is significantly overexpressed in PCa compared to non-
tumorous prostate cells, was introduced as a biomarker for
PCa to show high sensitivity (52 % to 58 %) and specificity
(72 % to 87 %) [11–16]. The US FDA approved PCA3 as a
risk assessment tool for PCa to guide prostatic biopsydistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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ary PCA3 assay combined with TMPRSS2:ERG is reported
to improve the diagnostic accuracy [17, 18]. Recently re-
ported studies suggested that these requirements could be
fulfilled using the diagnostic approach based on analysis of
urine, which has become the future for non-invasive
biomarker testing [10, 19].
This brief debate article is to discuss ad seek to
characterize the circulating microRNAs (miRNAs) in
urine with regard to PCa. We aim to provide our audi-
ence the current knowledge, in particular, focused on
clinical implication as a liquid biopsy with a clinically
satisfactory degree of sensitivity and specificity.Discussion
MicroRNAs in prostate cancer
What are microRNAs?
Small non-coding microRNA (miRNA) molecules are
known as post-transcriptional regulators involved in the
regulation of gene and protein expression by interfering
in the post-transcriptional level, resulting in the degrad-
ation and translation inhibition of mRNAs. Approximately
more than 2,000 mature human miRNAs have been re-
ported so far. These miRNAs are short (19–24 nt) and
low molecular weight RNAs. miRNAs are derived from
hairpin-like precursor transcripts (pre-miRNAs) and
taken out of nucleus by a mediator protein, exportin 5.
Pre-miRNA is then cleaved by Dicer (a ribonuclease III
enzyme) to excise the mature miRNAs in the form of
siRNA-like duplexes and asymmetrical assembling of
the mature miRNA strands. Since miRNAs interact
with multiple messenger RNAs by binding the pairing
of bases of the mRNAs and repress target gene expres-
sion, and regulate mRNA cleavage and mRNA decay
initiated by the miRNA-guided rapid deadenylation,
miRNAs have a wide variety of functions contributing
to various pathological conditions including prostate
cancer [20].Fig. 1 miRNAs upregulated in PCaHow miRNAs are connected with PCa development and
progression cancer?
Many of miRNAs play roles in cell proliferation and
apoptosis processes, thus miRNA expression profiles
can be considered as useful biomarkers monitoring
many types of cancer progression and treatment re-
sponses [21]. Previous studies have suggested several
miRNA biomarker candidates associated with PCa [22].
miR-548c-3p was found significantly overexpressed in
CRPC. Expression levels of miR-548c-3p negatively cor-
related with recurrence-free survival. miR-375 was sig-
nificantly downregulated in 83.5 % of PC patients
compared to BPH controls. Metastatic CRPC patients
with chemotherapy-resistant had the higher miR-21
levels compared with those with hormone dependent
primary PCa. A combined diagnostic testing of miR-21
and PSA could stratify patients effectively. miR-21 was
introduced as one of miRNAs of a multiple diagnostic
profile, which includes miR-21,miR-141, and miR-221.
miR-141 was independently identified as a biomarker
of CRPC. Another combination panel of PSA and ex-
pression levels of let-7c, miR-30c, miR-141, and miR-
375 was suggested as diagnostic biomarkers for PCa
screening outperforming the PSA testing alone. Some
PCa-specific miRNAs were identified from mouse PCa
model. A set of 46 miRNAs in the serum of transgenic
mice with advanced adenocarcinoma PCa were identi-
fied. Among those, miR-141, miR-298, and miR-375
were found to be elevated in the serum of metastatic
CRPC patients. In particular, miR-141 and miR-375
showed a correlation with disease outcome. Diagram-
matic representation of miRNAs associated with PCa is
shown in Fig. 1.
What can be the target genes or pathways of miRNAs in
PCa?
In the accumulated literature the roles of miRNAs in the
pathobiology of PCa were found in cell cycle, apoptosis,
epithelial to mesenchymal transition (EMT) and
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vasion and metastasis, PCa stem cell, and androgen re-
ceptor (AR) pathway. PTEN-PI3 Kinase-AKT, EGFR
and AR pathways are considered as the most important
signaling pathways in PCa. Upregulation of miR-221/-
222 in PCa suggest a mechanistic link to PCa since
miR-221/-222 plays a role in AR pathway regulation, c-
kit, PTEN, and TIMP3 et al. miR-124 was characterized
to have a direct targeting of AR thereby inducing
down-regulation of miR-125b and up-regulation of p53.
When miR-125b is suppressed miR-125b effectors (p52,
Puma, Bak1, and p14ARF) were downregulated. The
regulation of miR-125b on apoptotic proteins (mitochon-
drial cytochrome C and Caspase-3) and NCOR2 (a co-
repressor of AR) was well known. Another PCa-
associated miRNA, miR-let-7c regulates AR pathway
and involves in the conversion of hormone dependent
PCa to CRPC.
Urinary microRNAs as prostate cancer biomarkers
Several cancer-associated miRNAs were found in cir-
culating body fluids such as urine, which make it
possible to develop non-invasive biomarkers mainly
due to their ease of access and stability. Only few
studies for PCa-associated miRNA in urine were re-
ported. Five of the miRNAs that were differentially
quantified in PCa patients compared to controls
(miR-107, miR-574-3p, miR375, miR200b and miR-
141) were successfully quantified in urine of men
with cancer, which were much higher in PCa pa-
tients than that of healthy volunteers. Such reports
provide evidence that circulating miRNAs might be a
next-generation biomarker and contribute to cancer
screening in non-invasive liquid biopsy. Two add-
itional promising miRNAs, miR-141 and miR-375
were found in the patient blood. In particular, data
from this study showed that metastatic PCa patients
have approximately 50 fold higher miR-141 levels,
compared to the healthy individuals.
Virus infection and prostate cancer
Among the various viruses, herpes virus is one of the
viruses most commonly related to carcinogenesis. Sev-
eral epidemiological studies evaluated the association
between herpes virus infection and prostate cancer risk,
although results were inconsistent. Herpes virus plays
an important role in the pathogenesis of cancer via the
inhibition of cell apoptosis and stimulation of DNA
synthesis, which may ultimately lead to PC. Previous
meta-analysis indicated that infection by herpes sim-
plex virus type 2 (HSV-2) or human herpesvirus 8
(HHV-8) may be associated with a higher prostate can-
cer risk. However, there has not been a study to eluci-
date the potential mechanism of HSV-2 infectionunderlying viral PC carcinogenesis. A potential link be-
tween HPV infection and PCa risk was attempted to
study the causal role of HPV-16 in prostate carcino-
gens. A significant increase of PCa risk related with
HPV-16 infection was observed. However, this is still
contradictory since other epidemiological studies could
not find same association [23–25]. Therefore, an elab-
orate and comprehensive demonstration of the associ-
ation between herpes virus infection and prostate
cancer risk is of significance [24]. Further investigations
and large-sample studies are required to and the rela-
tionship between herpes virus infection and prostate
cancer risk.
Our recent findings demonstrated the overexpression
of herpes virus-encoded miRNAs in urine samples from
prostate cancer patients, compared to those of control
subjects [19]. Interestingly, hsv1-miR-H18 and hsv2-
miR-H9-5p detected in urine samples showed better
diagnostic performance than tPSA levels in patients
within the PSA grey zone. A recent meta-analysis
showed that HSV infection is associated with an in-
creased PCa risk, however, it remains puzzling how
these two particular vir-miRNAs contribute to PCa. To
better understand the biological contribution of hsv1-
miR-H18 and hsv2-miR-H9-5p to PCa, the geographic
distribution, gender difference and socioeconomic vari-
ation of virus infection and their possible impact on
prostate cancer should be considered to investigate
(Fig. 2).Viral miRNAs circulating through biofluids
Viruses also encode their own sets of miRNAs, which
they use to control the expression of either the host's
genes and/or their own. In the past few years’ evidence
of the presence of cellular miRNAs in extracellular hu-
man body fluids such as serum, plasma, saliva, and urine
has been accumulated [26, 27]. Furthermore, it has been
also demonstrated that miRNAs secreted by virus-
infected cells are transferred to and act in uninfected re-
cipient cells [19].
The first viral-encoded miRNAs was found in cells in-
fected with EBV [27, 28]. The majority of natural viruses
found to encode miRNAs. In DNA viruses (such as her-
pes virus, polyomavirus, ascovirus, baculovirus, irido-
virus, and adenovirus families), a DNA component to
replication cycle can exploit the initiating host miRNA
biogenesis machinery in the nucleus, where they repli-
cate and cause long-term persistent infections. Among
DNA viruses, which account for the majority of known
virus-encoded miRNAs, 95 % of viral miRNAs known
today are of herpes virus origin. However, little has been
identified about the role of circulating miRNAs from the
virus-infected cells.
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Fig. 2 Diagnostic performance of urinary hsv1-miR-H18 and hsv2-miR-H9-5p compared with serum PSA levels (published data) [19]. a Overview
of the study design. A heatmap representing miRNA microarray data suggested that miRNA signature segregates PCa from BPH controls (right).
b ROC curves for all patients. c ROC curves for patients only within the PSA grey zone (3–10 ng/ml)
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prostate cancer
Cells can release different types of vesicles, which have
been difficult to categorize in a definitive manner. The
transmission of vesicles from cancer cells to other cell
types has been the subject of intensive studies in recent
years. It is a process that can make it possible a sophisti-
cated form of cellular communication through the deliv-
ery of highly complex and dynamic cargo. As a delivery
vehicle between cells, extracellular vesicles (EV) have
been considered as a molecular cargo mediating a
communication between cells in the microenviron-
ment. Although EV were originally considered to be a
means for exclusion of garbage molecules from cells,
it is now clear that EV alter signaling pathways and
have a biological influence in neighboring cells [29].Also, since EV have the bioactivity of their molecular
cargo and can be readily isolated from multiple bio-
logical fluids (e.g., urine, serum, plasma, pleural effu-
sion, saliva), EV has been considered as a non-invasive
biomarker candidate [30–32].
There are multiple types of EV, the small sealed mem-
brane vesicles that are produced from cells differing in
size, biology, contents, and secretory mechanisms. Exo-
somes and microparticles (MPs) are two distinct groups
of EV. Exosomes are originated from the inward bud-
ding of the limiting membrane of multivesicular bodies
(MVBs), while MPs are in bigger size vesicles formed by
the outward membrane budding. Vesicles that are pro-
duced from cells during cell death are apoptotic bodies.
It is known that PCa patients had higher levels of urin-
ary exosomes than the healthy donors. The membranes
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lytic activity of urine, indicating that exosomes are quite
stable in urine. PC cell-derived EV can deliver various
genetic factors such as nucleic acids, including DNA,
mRNA, miRNA, and small non-coding RNAs, as well as
oncoproteins and metabolites, leading to the horizontal
transfer of oncogenic information to neighboring
immune cells, vessel cells, or cancer cells [33, 34]. EV-
mediated RNA transfer provides benefits as a communica-
some [35–37]. However, little is known how EV-mediated
transfer of these molecules enters into recipient cells, and
how specific miRNA species can be sorted into EV. Our
series of publications in this field suggest that EV shedding
can influence on microenvironment of PCa by modulating
immune cell proliferation and activation [38].
EV influence immune response in prostate cancer
Role of immune response caused/mediated by miRNA was
suggested by a series of studies showing that EV-derived
miRNAs participate in the regulation of inflammatory re-
sponses. A recent report from our group demonstrated that
EV derived from amoeboid phenotype of prostate cell may
influence the immune response of the tumor microenviron-
ment. A tritiated thymidine (3H-thymidine) incorporation
assay revealed that EV contain miRNAs (e.g., miR-125a),
which are transferred to tumor microenvironment leading
to proliferative inhibition of immune cells. Other interest-
ing findings suggest immune response may be mediated by
miRNAs regulating Toll-like receptors (TLRs), which play
an important role in immune response and inflammation
including tissue repair and tissue injury-induced in-
flammation. In PCa cell lines, several miRNAs (e.g.,
has-miR-29b, −29c, −148b, and −152) were upregulated
by TLR3 activation, leading to antitumoral effects on
PCa. EV derived from dendritic cells contain miR-155
(a promoter of inflammatory responses) and miR-146a
(a mediator of immune suppression), which are known
as important players to regulate inflammation, alter the
gene expression of inflammation related targets and
reprogramm the response to endotoxin [39, 40].
EV released from virus-infected cells
In virology field, biology of extracellular vesicles are well
understood compared to cancer mainly because virus
should be enveloped to be released from infected host.
The accumulating evidence suggests that viruses, such
as retroviruses, hepatitis C virus, herpes simplex virus,
Epstein-Barr virus, Coxsackie virus B3 (CVB3), utilize
the cellular vesiculation pathway for budding and assem-
bly, immune evasion, and intercellular communication.
It is also well known that many virally infected cells se-
crete vesicles (most of cases, exosomes) containing various
viral proteins and genetic materials such as RNAs. Studies
on herpes simplex virus-infected cells demonstrated thatvirus communicate via vesicles. In the case of Epstein-
Barr virus, recent reports suggested that herpes virus uti-
lizes exosomes, one kind of extracellular vesicles, as a
mechanism of cell-to-cell communication and transfers
signaling competent proteins and functional miRNAs to
uninfected neighbor cells. For example, exosomes released
from infected cells have been shown to contain co-
receptors for HIV, which can enhance virus entry into
cells. Proteins in the secreted exosomes from virus-
infected cells can induce apoptosis in CD4 T cells, and
contribute innate immune response.
EV as cargoes to deliver viral miRNAs
EV-mediated communication would allow the virus to re-
spond to the cellular microenvironment. Virus-infected
cells continuously shed and transfer EV to uninfected
neighboring cells. Throughout EV shedding and secretion
to extracellular space, the virus-encoded miRNAs were
delivered to other cells, leading to alteration of miRNA-
mediated gene repression and intercellular communica-
tion. Thus, the presence of viral-encoded miRNAs in EV
suggests that virus-infected cells perturb gene expression
in the surrounding tissue, resulting in destruction of the
immune system. Exosomes secreted from HIV-infected al-
veolar macrophages have been identified to carry viral
miRNA (vir-miRNA) such as vmiR88, vmiR99, and vmiR-
TAR. It has not been clearly identified how vir-miRNA
composition is decided and recruited to EV. Vir-miRNAs
might have a role in cancer initiation by blocking of major
tumor suppressors (e.g., p53) or acceleration of cancer
development by evading cellular immune response
(e.g., mi17-92).
These findings still raise a number of exciting ques-
tions. Does virus-infected prostate cells secrete miRNAs
using EV as a cargo? What are the target genes of the
abundantly secreted viral miRNAs? Are extracellular
vesicles shed only in the absence of viral replication? Is
there any evidence for functional miRNA delivery
in vivo? If so, what’s the biological mechanism? In
addition, the detail mechanism is currently lacking
whether virus infection promotes miRNAs sorting into
EV, or whether this secretion is a selective and specific
process.
Conclusions
In PCa biomarker development, the greatest unmet need
remains: a biomarker that stratifies men at risk of ag-
gressive PCa or a biomarker that identify the early stage
of patients who need active surveillance, eventually lead-
ing to a reduction of unnecessary interventions. Al-
though miRNAs might have many useful clinical
applications for patients with PCa, many additional stud-
ies are warranted to clarify their function and regulation
during tumorigenesis and tumor progression. The
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ing PCa progression would have the potential that PCa
patients can be molecularly stratified based on their
miRNAs profile in urine samples. In addition, the studies
could uncover important clues about underlying disease
mechanisms.
Urine analyses have great potential to be adapted in
clinical practice, based on its non-invasiveness. Identifi-
cation of non-invasive clinical indicators of PCa would
be one of the most important advances achievable in this
field. Our current mechanistic understanding of shed-
ding vesicle biology and function, especially in the con-
text of virus infection and communication with host, is
not mature enough. Identification of potential candidates
of the circulating miRNAs signature in patient urine
samples would have significant implications for an alter-
native and/or supportive diagnostic tool for PCa.
Unnecessary diagnostic procedures would be mini-
mized for patients with early stage of PCa, contributing
to the easier diagnostic assessment and to the reducing
associated public health and economic burden to pa-
tients. In addition, the studies to understand role and
biology of the circulating miRNAs have significant clin-
ical relevance to public health since it will improve
accuracy of predicting patient survival, identifying re-
sponsiveness candidates of PCa patients. Furthermore,
we envision that this study will also provide the mechan-
istic data to address the long-term goal of the PCa field
identifying new treatments tailoring more specific and
effective therapies for PCa, thus it holds great promise
for the treatment of high risk PCa patients.
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